FrancophonIA/ELRC3.0 huggingface dataset:
English: No data are available to support the combination of Atripla and other antiretroviral agents.
Slovenian: Podatkov, ki podpirajo kombinacijo zdravila Atripla in drugih protiretrovirusnih zdravil, ni na voljo.
English: Atripla may reduce the amount of atovaquone/proguanil or artemether/lumefantrine in your blood.
Slovenian: Zdravilo Atripla lahko zmanjša količino atovakvona/progvanila ali artemetra/lumefantrina v vaši krvi.
English: In some patients with advanced liver disease or cirrhosis, stopping treatment is not recommended as this may lead to worsening of your hepatitis, which may be life-threatening.
Slovenian: Pri nekaterih bolnikih z napredovalo jetrno boleznijo ali cirozo jeter prekinitev zdravljenja ni priporočljiva, ker lahko povzroči poslabšanje hepatitisa, kar je lahko smrtno nevarno.
English: Cmax (ng/ml) 2,264.3
Slovenian: Cmax (ng/ml) 2.264,3 AUC0-konec (ng∙h/ml)
English: Before starting treatment, your doctor may order blood tests to assess kidney function.
Slovenian: Pred začetkom zdravljenja vam lahko zdravnik predpiše krvne preiskave za oceno delovanja ledvic.
English: Side effects to the liver: If you are also infected with hepatitis B virus, you may experience a worsening of hepatitis after discontinuation of treatment (see section 3).
Slovenian: Neželeni učinki na jetra: če ste okuženi z virusom hepatitisa B, se vam lahko po prekinitvi zdravljenja hepatitis poslabša (glejte poglavje 3).
English: Concomitant administration with Atripla should be avoided due to the risk for QTc prolongation (see section
Slovenian: Potrebno se je izogibati sočasni uporabi z zdravilom Atripla zaradi nevarnosti podaljšanja intervala QTc (glejte poglavje 4.3)
English: All 3 subjects had received a fixed dose combination of lamivudine and zidovudine (Combivir) and efavirenz for 144 weeks and then switched to Atripla.
Slovenian: Vse 3 osebe so 144 tednov dobivale fiksno kombinacijo odmerkov lamivudina in zidovudina (Combivir) ter efavirenz, nato pa so prešle na zdravilo Atripla.
English: Artemether/Lumefantrine/Emtricitabine Interaction not studied.
Slovenian: artemeter/lumefantrin/emtricitabin Interakcij niso preučevali.
English: If you throw up the tablet (within 1 hour after taking Atripla), you should take another tablet.
Slovenian: Če tableto izbruhate (v roku 1 ure po tem, ko ste vzeli zdravilo Atripla), morate vzeti drugo tableto.
English: Patients with liver disease including chronic hepatitis B or C, who are treated with combination antiretrovirals, have a higher risk of severe and potentially life-threatening liver problems.
Slovenian: Pri bolnikih z boleznijo jeter, vključno s kroničnim hepatitisom B ali C, ki prejemajo kombinacijo protiretrovirusnih zdravil, je tveganje za hude in morebitno smrtno nevarne bolezni jeter večje.
English: Efavirenz: Non-clinical safety pharmacology studies on efavirenz reveal no special hazard for humans.
Slovenian: Efavirenz: Predklinične študije farmakološke varnosti efavirenza ne kažejo posebnega tveganja za človeka.
English: If Atripla is co-administered with an NSAID, renal function should be monitored adequately.
Slovenian: Pri sočasnem jemanju zdravila Atripla z NSAID je treba ustrezno nadzorovati ledvično funkcijo.
English: Patients with renal impairment: Since tenofovir disoproxil can cause renal toxicity, close monitoring of renal function is recommended in any patient with mild renal impairment treated with Atripla (see sections 4.2, 4.4 and 5.2).
Slovenian: Bolniki z ledvično okvaro: Ker lahko dizoproksiltenofovirat povzroči ledvično toksičnost, se priporoča skrbno nadziranje ledvične funkcije pri vseh bolnikih z blago ledvično okvaro, zdravljenih z zdravilom Atripla (glejte poglavja 4.2, 4.4 in 5.2).
English: Hepatic failure with efavirenz: Hepatic failure, including cases in patients with no pre-existing hepatic disease or other identifiable risk factors, as reported post-marketing, were sometimes characterised by a fulminant course, progressing in some cases to transplantation or death.
Slovenian: Jetrna odpoved pri efavirenzu: Za postmarketinška poročila o jetrni odpovedi, vključno s primeri bolnikov brez predhodne bolezni jeter ali drugih opredeljenih dejavnikov tveganja, je bil včasih značilen bliskovit potek, ki je v nekaterih primerih pripeljal do presaditve ali smrti.
English: There is insufficient information on the effects of efavirenz, emtricitabine and tenofovir in newborns/infants.
Slovenian: Podatki o učinku efavirenza, emtricitabina in tenofovirja na dojene novorojence/otroke so nezadostni.
English: The following pack sizes are available: outer cartons containing 1 bottle of 30 film-coated tablets and 90 (3 bottles of 30) film-coated tablets.
Slovenian: Na voljo so naslednje velikosti pakiranj: škatle, ki vsebujejo po 1 plastični vsebnik s 30 filmsko obloženimi tabletami ali po 90 filmsko obloženih tablet (3 vsebniki po 30 tablet).
English: No effect (↔) equals a decrease in mean ratio estimate of ≤ 20% or increase in mean ratio estimate of
Slovenian: Brez vpliva (↔) ustreza zmanjšanju povprečnega odstotka za ≤ 20 % ali zvečanju povprečnega odstotka za
English: Prior NNRTI-based regimen (N=104)
Slovenian: Predhodno zdravljenje z NNRTI (N = 104)
English: Therefore co-administration of atazanavir/ritonavir and Atripla is not recommended (see Table 1).
Slovenian: Zato sočasne uporabe atazanavirja/ritonavirja in zdravila Atripla ne priporočamo (glejte tabelo 1).
English: The K65R mutation can also be selected by abacavir or didanosine and results in reduced susceptibility to these agents plus lamivudine, emtricitabine and tenofovir.
Slovenian: Mutacijo K65R lahko izberemo tudi z abakavirjem ali didanozinom, kar povzroči zmanjšano občutljivost za ta zdravila ter za lamivudin, emtricitabin in tenofovir.
English: Levonorgestrel (active metabolite):
Slovenian: levonorgestrel (aktivni presnovek):
English: A multiple-dose study of efavirenz showed no significant effect on efavirenz pharmacokinetics in patients with mild hepatic impairment (Child-Pugh-Turcotte Class A) compared with controls.
Slovenian: Študija efavirenza z več odmerki ni pokazala značilnega učinka na farmakokinetiko efavirenza pri bolnikih z blago jetrno okvaro (razreda A po Child-Pugh-Turcotteovi lestvici) v primerjavi s kontrolnimi skupinami.
English: In in vitro studies efavirenz did not inhibit CYP2E1 and inhibited CYP2D6 and CYP1A2 only at concentrations well above those achieved clinically.
Slovenian: V raziskavah in vitro efavirenz ni zaviral izocima CYP2E1, izocima CYP2D6 in CYP1A2 pa je zaviral šele pri koncentracijah, ki so bile precej večje od tistih, ki jih dosežemo pri klinični uporabi zdravila.
English: Uncommon anaemia1
Slovenian: Občasni anemija1
English: The in vitro studies suggest that CYP3A4 and CYP2B6 are the major isozymes responsible for efavirenz metabolism and that it inhibits CYP isozymes 2C9, 2C19, and 3A4.
Slovenian: Raziskave in vitro kažejo, da sta CYP3A4 in CYP2B6 glavna izocima, odgovorna za presnovo efavirenza, ter da zavirata izocime CYP 2C9, 2C19 in 3A4.
English: Nervous system symptoms
Slovenian: Simptomi živčevja
English: Your doctor may consider giving you an alternative medicine or changing the dose of the protease inhibitors.
Slovenian: Zdravnik vam bo morda predpisal drugo zdravilo ali vam spremenil odmerek zaviralca proteaze.
English: How to take Atripla
Slovenian: Kako jemati zdravilo Atripla
English: What Atripla looks like and contents of the pack
Slovenian: Izgled zdravila Atripla in vsebina pakiranja
English: Insufficient numbers of patients over 65 years of age have been studied.
Slovenian: Raziskav niso opravili pri zadostnem številu oseb, starejših od 65 let.
English: Elderly patients are more likely to have decreased hepatic or renal function, therefore caution should be exercised when treating elderly patients with Atripla (see section 4.2).
Slovenian: Pri starejših bolnikih je bolj verjetno, da imajo zmanjšano delovanje jeter ali ledvic, zato je pri uporabi zdravila Atripla pri starejših bolnikih potrebna previdnost (glejte poglavje 4.2).
English: • feeling weak
Slovenian: • občutek šibkosti.
English: Clinically significant interactions have not been found and would not be expected since the NRTIs are metabolised via a different route than efavirenz and would be unlikely to compete for the same metabolic enzymes and elimination pathways.
Slovenian: Klinično pomembne interakcije niso ugotovili in jih ni pričakovati, saj se zdravila iz skupine NRTI presnavljajo po drugi poti kot efavirenz in ni verjetno, da bi prišlo do kompeticije za iste presnovne encime in poti izločanja.
English: After oral administration, emtricitabine is widely distributed throughout the body.
Slovenian: Po peroralni uporabi se emtricitabin porazdeli po vsem telesu.
English: - The other ingredients in the tablet are croscarmellose sodium, hyprolose, magnesium stearate, microcrystalline cellulose, sodium laurilsulfate.
Slovenian: - Pomožne snovi v tableti so natrijev karmelozat, hiproloza, magnezijev stearat, mikrokristalna celuloza, natrijev lavrilsulfat.
English: Similar results were found by other investigators, although the MPA plasma levels were more variable in the second study.
Slovenian: čeprav so bile koncentracije MPA v plazmi v drugi študiji bolj spremenljive.
English: QT Prolonging Drugs: Atripla is contraindicated with concomitant use of drugs that are known to prolong the QTc interval and could lead to Torsade de Pointes, such as: antiarrhythmics of classes IA and III, neuroleptics and antidepressant agents, certain antibiotics including some agents of the following classes: macrolides, fluoroquinolones, imidazole, and triazole antifungal agents, certain non-sedating antihistaminics (terfenadine, astemizole), cisapride, flecainide, certain antimalarials and methadone (see section 4.3).
Slovenian: Zdravila, ki podaljšajo interval QT: Zdravilo Atripla je kontraindicirano pri sočasni uporabi zdravil, za katera je znano, da povzročajo podaljšanje intervala QTc in lahko vodijo v torsade de pointes, kot so: antiaritmiki razreda IA in III, nevroleptiki in antidepresivi, določeni antibiotiki, vključno z nekaterimi učinkovinami iz naslednjih razredov: makrolidi, fluorokinoloni, imidazoli in triazolski antimikotiki, določeni nesedativni antihistaminiki (terfenadin, astemizol), cisaprid, flekainid, določeni antimalariki in metadon (glejte poglavje 4.3).
English: Consider doubling the rifabutin dose in regimens where rifabutin is given 2 or 3 times a week in combination with Atripla.
Slovenian: Pri režimih, kjer se rifabutin daje 2- ali 3-krat na teden v kombinaciji z zdravilom Atripla, je treba razmisliti o možnosti podvojitve odmerka rifabutina.
English: Elderly: Atripla has not been studied in patients over the age of 65.
Slovenian: Starejši: Zdravila Atripla niso preučevali pri bolnikih, starejših od 65 let.
English: In vitro and clinical pharmacokinetic interaction studies have shown the potential for CYP-mediated interactions involving emtricitabine and tenofovir disoproxil with other medicinal products is low.
Slovenian: Študije in vitro in klinične študije farmakokinetičnih interakcij so pokazale, da je možnost za interakcije, pri katerih posreduje CYP in vključujejo emtricitabin in dizoproksiltenofovirat, z drugimi zdravili majhna.
English: - antiarrhythmics of classes IA and III, - neuroleptics, antidepressive agents, - certain antibiotics including some agents of the following classes: macrolides,
Slovenian: Med taka zdravila sodijo: - antiaritmiki razreda IA in III, - nevroleptiki, antidepresivi, - določeni antibiotiki, vključno z učinkovinami iz naslednjih razredov: makrolidi, fluorokinoloni,
English: Maraviroc:
Slovenian: maravirok:
English: Administration of efavirenz capsules with a high fat meal increased the mean AUC and Cmax of efavirenz by 28% and 79%, respectively, compared to administration in a fasted state.
Slovenian: Uporaba kapsul efavirenza ob obroku z veliko količino maščob je povečala vrednost AUC za 28 %, vrednost Cmax pa za 79 %, v primerjavi z uporabo na tešče.
English: Women of childbearing potential should undergo pregnancy testing before initiation of Atripla.
Slovenian: Pri ženskah v rodni dobi je treba pred začetkom zdravljenja z zdravilom Atripla opraviti test nosečnosti.
English: Substantial decrease in lopinavir exposure, necessitating dosage adjustment of lopinavir/ritonavir.
Slovenian: Zaradi znatnega zmanjšanja izpostavljenosti lopinavirju je bilo treba prilagoditi odmerek lopinavirja/ritonavirja.
English: Emtricitabine: Non-clinical data on emtricitabine reveal no special hazard for humans based on conventional studies of safety pharmacology, repeated-dose toxicity, genotoxicity, carcinogenic potential, and toxicity to reproduction and development.
Slovenian: Emtricitabin: Predklinični podatki o emtricitabinu na osnovi običajnih študij farmakološke varnosti, toksičnosti pri ponavljajočih se odmerkih, genotoksičnosti, kancerogenega potenciala in toksičnosti na sposobnost razmnoževanja in razvoja ne kažejo posebnega tveganja za človeka.
English: Efavirenz, emtricitabine and tenofovir have been shown to be excreted in human milk.
Slovenian: Efavirenz, emtricitabin in tenofovir se izločajo v materino mleko.
English: When Atripla is taken with rifampicin in patients weighing 50 kg or greater, an additional 200 mg/day (800 mg total) of efavirenz may provide exposure similar to a daily efavirenz dose of 600 mg when taken without rifampicin.
Slovenian: Če se zdravilo Atripla uporablja sočasno z rifampicinom pri bolnikih s telesno maso 50 kg ali večjo, lahko dodatni odmerek 200 mg efavirenza na dan (skupno 800 mg) omogoči izpostavljenost zdravilu, podobno dnevnemu odmerku efavirenza 600 mg, če se vzame brez rifampicina.
English: - bone problems.
Slovenian: težave s kostmi.
English: Atripla must not be used in patients with severe hepatic impairment (see section 4.3) and is not recommended for patients with moderate hepatic impairment.
Slovenian: Zdravilo Atripla se ne sme uporabljati pri bolnikih s hudo jetrno okvaro (glejte poglavje 4.3) in se ne priporoča za bolnike z zmerno jetrno okvaro.
English: Rare events of renal impairment, renal failure and uncommon events of proximal renal tubulopathy (including Fanconi syndrome) sometimes leading to bone abnormalities (infrequently contributing to fractures) have also been reported.
Slovenian: Poročali so tudi o redkih dogodkih okvare ledvic, ledvične odpovedi in občasnih dogodkih proksimalne renalne tubulopatije (vključno s Fanconijevim sindromom), ki so včasih povzročili nenormalnosti kosti (ki so redko prispevale k zlomom).
English: Co-administration with elbasvir/grazoprevir due to the expected significant decreases in plasma concentrations of elbasvir and grazoprevir.
Slovenian: Sočasna uporaba z elbasvirjem/grazoprevirjem zaradi pričakovanega pomembnega zmanjšanja koncentracije elbasvirja/grazoprevirja v plazmi.
English: The biliary hyperplasia regressed upon cessation of dosing.
Slovenian: Biliarna hiperplazija je po prekinitvi odmerjanja minila.
English: Pharmacokinetic parameters were determined following administration of single doses of the individual preparations of emtricitabine 200 mg or tenofovir disoproxil 245 mg to non-HIV infected patients with varying degrees of renal impairment.
Slovenian: Farmakokinetične parametre so določili po uporabi enkratnih odmerkov 200 mg emtricitabina ali 245 mg dizoproksiltenofovirijevega pri bolnikih, ki niso bili okuženi s HIV, z različnimi stopnjami ledvične okvare.
English: The degree of renal impairment was defined according to baseline creatinine clearance (normal renal function when creatinine clearance > 80 ml/min; mild impairment with creatinine clearance=50 to 79 ml/min; moderate impairment with creatinine clearance=30 to 49 ml/min and severe impairment with creatinine clearance=10 to 29 ml/min).
Slovenian: Stopnja ledvične okvare je bila opredeljena glede na začetno vrednost kreatininskega očistka (ClCr) (normalno delovanje ledvic je pri kreatininskem očistku ClCr > 80 ml/min, blaga okvara pri ClCr = 50-79 ml/min, zmerna okvara pri ClCr = 30-49 ml/min, huda okvara pa pri ClCr = 10-29 ml/min).
English: HIV/HBV or HCV co-infected patients: Only a limited number of patients were co-infected with HBV (n = 13) or HCV (n = 26) in study GS-01-934.
Slovenian: Bolniki, sočasno okuženi z virusi HIV in HBV ali HCV: V študijo GS-01-934 je bilo vključeno le manjše število bolnikov, sočasno okuženih z virusom HBV (n = 13) ali HCV (n = 26).
English: The potential for cross-resistance between efavirenz and NRTIs is low because of the different binding sites on the target and mechanism of action.
Slovenian: Možnost za navzkrižno odpornost med efavirenzom in zdravili NRTI je majhna zaradi različnih vezavnih mest in različnega mehanizma delovanja.
English: Interaction with didanosine: Co-administration of Atripla and didanosine is not recommended as it results in a 40-60% increase in systemic exposure to didanosine that may increase the risk of didanosine-related adverse reactions (see section 4.5).
Slovenian: Interakcije z didanozinom: Sočasno dajanje zdravila Atripla in didanozina se ne priporoča, saj povzroči 40-60 % zvišanje sistemske izpostavljenosti didanozinu, kar lahko poveča tveganje neželenih reakcij, povezanih z didanozinom (glejte poglavje 4.5).
English: Limited data suggest that Asian and Pacific Island patients may have higher exposure to efavirenz but they do not appear to be less tolerant of efavirenz.
Slovenian: Pomanjkljivi podatki kažejo, da je lahko pri bolnikih ženskega spola in pri bolnikih iz Azije ali s Pacifiških otokov izpostavljenost efavirenzu večja, a ne kaže, da bi le-ti zdravilo prenašali slabše.
English: Since no dose recommendation can be made for itraconazole when used with Atripla, an alternative antifungal treatment should be considered.
Slovenian: Ker za kombinacijo zdravila Atripla in itrakonazola ni mogoče dati priporočila za odmerjanje, je treba pretehtati možnost uporabe drugega antimikotika.
English: Decreased exposure of etonogestrel may be expected (CYP3A4 induction).
Slovenian: Pričakuje se lahko zmanjšana izpostavljenost etonogestrelu (indukcija CYP3A4).
English: In patients with a history of renal dysfunction or in patients who are at risk of renal dysfunction, a more frequent monitoring of renal function is required.
Slovenian: Pri bolnikih z motnjami v delovanju ledvic v anamnezi ali pri bolnikih s tveganjem za motnje v delovanju ledvic, je treba pogosteje spremljati delovanje ledvic.
English: Voriconazole: Co-administration of standard doses of efavirenz and voriconazole is contraindicated.
Slovenian: Vorikonazol: Sočasna uporaba standardnih odmerkov efavirenza in vorikonazola je kontraindicirana.
English: Your doctor may also order blood tests during treatment to monitor your kidneys.
Slovenian: Zdravnik lahko krvne preiskave za nadzorovanje delovanja ledvic naroči tudi med potekom zdravljenja.
English: Nervous system symptoms associated with efavirenz usually begin during the first one or two days of therapy and generally resolve after the first two to four weeks.
Slovenian: Simptomi živčevja, povezani z uporabo efavirenza, se navadno pojavijo prvi dan ali v prvih dveh dnevih zdravljenja in na splošno minejo po prvih dveh do štirih tednih.
English: 4 This adverse reaction was identified through post-marketing surveillance for either efavirenz, emtricitabine or tenofovir disoproxil.
Slovenian: 4 Ta neželeni učinek je bil ugotovljen pri opazovanju po začetku trženja za bodisi efavirenz, emtricitabin ali dizoproksiltenofovirat.
English: Cmin: ↓ 8% (↑ 14 to ↓ 25)
Slovenian: Cmin: ↓ 8 % (↑ 14 do ↓ 25)
English: 1.2% (-2.3% to 6.7%)
Slovenian: 1,2 % (-2,3 % do 6,7 %)
English: Common diarrhoea, vomiting, abdominal pain, nausea elevated amylase including elevated pancreatic amylase, elevated serum lipase, vomiting, abdominal pain, dyspepsia abdominal pain, abdominal distension, flatulence
Slovenian: Pogosti driska, bruhanje, bolečine v trebuhu, navzea zvišana amilaza vključno z povišano pankreasno amilazo, povišanje serumske lipaze, bruhanje, bolečine v trebuhu, dispepsija bolečine v trebuhu, trebušna distenzija, flatulenca
English: 8.9% (-7.7% to 25.6%)
Slovenian: 8,9 % (-7,7 % do 25,6 %)
English: Therefore Atripla should not be used during breast-feeding.
Slovenian: Zdravilo Atripla se med dojenjem ne sme uporabljati.
English: Patients with HIV and hepatitis B (HBV) or C virus (HCV) co-infection Patients with chronic hepatitis B or C and treated with CART are at an increased risk for severe and potentially fatal hepatic adverse reactions.
Slovenian: Bolniki s sočasno okužbo z virusom HIV in s hepatitisom B (HBV) ali C (HCV) Pri bolnikih s kroničnim hepatitisom B ali C, ki prejemajo zdravljenje CART, je tveganje za hude in potencialno smrtne neželene učinke v jetrih povečano.
English: Study AI266073 was a 48-week open-label randomised clinical study in HIV infected patients comparing the efficacy of Atripla to antiretroviral therapy consisting of at least two nucleoside or nucleotide reverse transcriptase inhibitors (NRTIs) with a protease inhibitor or non-nucleoside reverse transcriptase inhibitor; however not a regimen containing all Atripla components (efavirenz, emtricitabine and tenofovir disoproxil).
Slovenian: Pri bolnikih, okuženih z virusom HIV, je bila izvedena 48-tedenska odprta randomizirana klinična študija AI266073, v kateri so učinkovitost zdravila Atripla primerjali z učinkovitostjo protiretrovirusnega zdravljenja z vsaj dvema nukleozidnima ali nukleotidnima zaviralcema reverzne transkriptaze (NRTI) z zaviralcem proteaze ali nenukleozidnim zaviralcem reverzne transkriptaze, vendar pa ne z režimom, ki bi vključeval vse tri učinkovine zdravila Atripla (efavirenz, emtricitabin in dizoproksiltenofovirat).
English: Relevant examples are cytomegalovirus retinitis, generalised and/or focal mycobacterial infections, and Pneumocystis jirovecii pneumonia.
Slovenian: Ustrezni primeri so citomegalovirusni retinitis, generalizirane in/ali žariščne splošne okužbe z mikobakterijami in pljučnica, povzročena s Pneumocystis jirovecii (nekoč znana kot Pneumocystis carinii).
English: Co-administration of efavirenz with atorvastatin, pravastatin, or simvastatin did not affect efavirenz AUC or Cmax values.
Slovenian: Sočasna uporaba efavirenza z atorvastatinom, pravastatinom ali simvastatinom ni vplivala na vrednosti AUC ali Cmax efavirenza.
English: The potential for cross-resistance between efavirenz and PIs is low because of the different enzyme targets involved.
Slovenian: Možnost navzkrižne odpornosti med efavirenzom in zaviralci proteaze je majhna, ker pri tem sodelujejo različni tarčni encimi.
English: Neither emtricitabine nor tenofovir inhibited in vitro drug metabolism mediated by any of the major human CYP isoforms involved in drug biotransformation.
Slovenian: Niti emtricitabin niti tenofovir in vitro nista zavirala presnavljanja zdravil, ki se biotransformirajo s katerokoli od pomembnejših glavnih izooblik humanega CYP.
English: Higher tenofovir concentrations could potentiate tenofovir-associated adverse events, including renal disorders.
Slovenian: Večje koncentracije tenofovirja bi lahko okrepile neželene učinke, povezane s tenofovirjem, vključno z motnjami delovanja ledvic.
English: (CYP3A4 induction)
Slovenian: (Indukcija CYP3A4)
English: Your doctor may need to consider changing your dose or giving you an alternative antibiotic.
Slovenian: Zdravnik vam bo morda moral spremeniti odmerek ali vam bo predpisal drug antibiotik.
English: Limited data suggest there is no clinically significant effect on valproic acid pharmacokinetics.
Slovenian: Nekaj podatkov kaže, da ni klinično pomembnega učinka na farmakokinetične parametre valprojske kisline.
English: Discontinuation of Atripla therapy in patients co-infected with HIV and HBV may be associated with severe acute exacerbations of hepatitis.
Slovenian: Prekinitev zdravljenja z zdravilom Atripla pri bolnikih s sočasno okužbo s HIV in HBV je lahko povezana s hudim akutnim poslabšanjem hepatitisa.
English: Headache has been reported in clinical studies with emtricitabine (see section 4.8).
Slovenian: V kliničnih študijah z emtricitabinom so poročali tudi o glavobolu (glejte poglavje 4.8).